Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Celebrex for juvenile RA panel review

Executive Summary

Pfizer's COX-2 inhibitor Celebrex (celecoxib) for the treatment of juvenile rheumatoid arthritis in patients two years of age and older will be discussed by FDA's Arthritis Advisory Committee Nov. 29. The committee overwhelmingly supported continued marketing of Celebrex during a much publicized 2005 joint meeting with the Drug Safety & Risk Management Advisory Committee on the COX-2 inhibitor class (1"The Pink Sheet" March 7, 2005, p. 21). The November meeting will be held at the Hilton in Gaithersburg, Md. from 8 a.m. to 5 p.m....

You may also be interested in...



Graham Meta-Analysis Ultimately Positive For Celebrex, Bextra

FDA Office of Drug Safety Associate Director for Science & Medicine David Graham's controversial presentation of unpublished studies on the safety of COX-2 inhibitors ultimately benefited certain COX-2s and raised questions about others in the class during a joint FDA advisory committee review

Stockwatch: Subdued Virtual J.P. Morgan Conference Prefaces Full-Year Earnings Season

Deals announced by Sanofi and Novartis at this year’s virtual J.P. Morgan Healthcare Conference and a smattering of full-year revenue preannouncements did not mark a bumper start to the year.

Government Report Outlines Costs, Savings Of Major Regs

The HHS was responsible for the most major regulations over the last few years of any agency, an OMB report shows.

UsernamePublicRestriction

Register

LL016481

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel